Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Dramatic response of diffuse osteosclerosis secondary to multiple myeloma using thalidomide with melphalan and prednisolone.

Mohamed M, Brain T, Khalafallah A.

J Clin Oncol. 2014 Aug 10;32(23):e85-7. doi: 10.1200/JCO.2012.48.0111. Epub 2014 Feb 10. No abstract available.

PMID:
24516032
2.

Thalidomide maintenance in multiple myeloma: certainties and controversies.

Cavo M, Pantani L, Tacchetti P, Pallotti MC, Brioli A, Petrucci A, Zamagni E, Tosi P.

J Clin Oncol. 2009 Nov 10;27(32):e186-7; author reply e188. doi: 10.1200/JCO.2009.24.0150. Epub 2009 Sep 21. No abstract available.

PMID:
19770366
3.

Thalidomide for the treatment of leptomeningeal multiple myeloma.

Yutaka H, Mariko Y, Shinichiro O, Kunihiko M, Yusuke T, Yasuo I.

Eur J Haematol. 2006 Apr;76(4):358-9. No abstract available.

PMID:
16519710
4.

[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].

Tsunemine H, Yoshioka S, Sakane E, Akasaka H, Ito K, Kodaka T, Takahashi T.

Gan To Kagaku Ryoho. 2015 May;42(5):605-7. Review. Japanese.

PMID:
25981655
5.

Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).

Eom HS, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, Jin JY, Do YR, Oh SJ, Suh C, Seong CM, Kim CS, Lee DS, Lee JH.

Ann Hematol. 2010 May;89(5):489-97. doi: 10.1007/s00277-009-0871-y. Epub 2009 Dec 10.

PMID:
20012045
6.

[Multiple myeloma].

Iida S.

Rinsho Ketsueki. 2012 Feb;53(2):155-63. Review. Japanese. No abstract available.

PMID:
22450574
7.

[Chemotherapy for multiple myeloma].

Ishida T.

Nihon Rinsho. 2007 Dec;65(12):2280-4. Review. Japanese.

PMID:
18069273
8.

Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.

Asou N, Izuno Y, Okubo T, Ide K, Ueno H, Kawakita M, Mitsuya H, Hata H.

Int J Hematol. 2007 Jul;86(1):69-71.

PMID:
17675270
9.

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.

Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A.

Blood. 2011 Nov 24;118(22):5759-66. doi: 10.1182/blood-2011-05-353995. Epub 2011 Sep 27.

10.

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N.

J Clin Oncol. 2009 Apr 10;27(11):1788-93. doi: 10.1200/JCO.2008.18.8573. Epub 2009 Mar 9.

PMID:
19273705
11.

Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.

Offidani M, Marconi M, Corvatta L, Olivieri A, Catarini M, Leoni P.

Haematologica. 2003 Dec;88(12):1432-3. No abstract available.

12.

Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.

Dimopoulos MA, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E, Kyrtsonis MC, Delibasi S, Vassou A, Pouli A, Zervas K, Anagnostopoulos N, Maniatis A; Greek Myeloma Study Group.

Haematologica. 2006 Feb;91(2):252-4.

13.

Current treatment for multiple myeloma.

Avigan D, Rosenblatt J.

N Engl J Med. 2014 Sep 4;371(10):961-2. doi: 10.1056/NEJMe1407442. No abstract available.

PMID:
25184869
14.

Bortezomib plus melphalan and prednisone for multiple myeloma.

Islam A, Ambrus JL.

N Engl J Med. 2008 Dec 11;359(24):2613; author reply 2613-4. doi: 10.1056/NEJMc086420. No abstract available.

15.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M.

J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12.

PMID:
20940200
16.

[Comparative studies of intermittent melphalan and prednisolone (MP) versus 5-drug regimen (QUVMP) and 3-drug regimen (QUP) in multiple myeloma].

Hoshino S, Saito H, Wada M, Akutsu M, Shiozaki H, Takanashi M, Takei Y, Tanaka S, Teramura M, Takada K, et al.

Rinsho Ketsueki. 1987 Mar;28(3):358-65. Japanese. No abstract available.

PMID:
3475485
17.

Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.

Witzens M, Moehler T, Neben K, Fruehauf S, Hartschuh W, Ho AD, Goldschmidt H.

Ann Hematol. 2004 Jul;83(7):467-70. Epub 2003 Nov 19.

PMID:
14625789
18.

Lenalidomide in myeloma--a high-maintenance friend.

Badros AZ.

N Engl J Med. 2012 May 10;366(19):1836-8. doi: 10.1056/NEJMe1202819. No abstract available.

PMID:
22571206
19.

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.

Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A.

Blood. 2009 Apr 9;113(15):3435-42. doi: 10.1182/blood-2008-07-169565. Epub 2008 Oct 27.

20.

[Combination chemotherapy with melphalan, cyclophosphamide, vincristine, ACNU and prednisolone (MEV(Ac)P) for multiple myeloma].

Takagi T, Oguro M, Sakai C.

Rinsho Ketsueki. 1986 Dec;27(12):2249-53. Japanese. No abstract available.

PMID:
3471977

Supplemental Content

Support Center